Tarsus Pharmaceuticals Inc. (TARS)
NASDAQ: TARS · Biological Products, (No Diagnostic Substances) · Irvine, CA
Our rating: Positive
Call changed from Cautious to Positive at $69.07, moderate conviction, November 4, 2026.
Breaks if: The positive tilt is wrong if Tarsus reports year-over-year net revenue growth below 35% for two consecutive quarters through the end of 2027 — signaling that its lead product's penetration has plateaued faster than the current ramp implies — or if annual free cash flow burn widens beyond -$60M in any reported twelve-month period without a disclosed pipeline catalyst of comparable commercial scale to justify the step-up in spending. Either condition would indicate the valuation multiple has gotten ahead of a deteriorating growth or cash story.
Key figures
| Market value | $3.6B |
|---|---|
| Revenue, last 12 months | $682M |
| Net income, last 12 months | −$702M |
| Free cash flow, last 12 months | $32M |
| Price to earnings | n/a |
| Free cash flow yield | 0.9% |
| Dividend yield | 0.0% |
| Operating margin | −102.0% |
| Return on equity | −319.8% |
| Beta to the S&P 500 | 0.58 |
| Volatility, annualized | 50.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $195M | 63.9% | $-14.40 | −$7M |
| June 30, 2026 | $174M | 69.4% | $-0.43 | $57M |
| March 31, 2026 | $162M | 106.9% | $-0.16 | −$30M |
| December 31, 2025 | $152M | 128.4% | $-0.19 | $13M |
| September 30, 2025 | $119M | 146.7% | $-0.30 | $16M |
| June 30, 2025 | $103M | 151.5% | $-0.48 | −$30M |
| March 31, 2025 | $78M | 183.7% | $-0.64 | −$21M |
| December 31, 2024 | $66M | 407.9% | $-0.59 | −$22M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.29B: Claude 18%, Gemini 25%, Mistral 15%
- Diluted earnings per share are above zero: Claude 8%, Gemini 5%, Mistral 20%
- Free cash flow for the quarter is at least $0.01B: Claude 38%, Gemini 55%, Mistral 35%
15 ledger entries and 24 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.